Jan Mares

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9460537/publications.pdf Version: 2024-02-01



IAN MADES

#	Article	IF	CITATIONS
1	Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics, 2022, 19, 753-773.	4.4	14
2	Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk. Neurotherapeutics, 2021, 18, 1654-1656.	4.4	1
3	Targeting B Cells to Modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	37
4	Targeting B cells to modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	30
5	Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 944.	2.4	0
6	Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis associated with multiple sclerosis in a 6â€month followâ€up. Acta Ophthalmologica, 2020, 98, 841-847.	1.1	5
7	Alemtuzumab: Rare serious adverse events of a high-efficacy drug. Multiple Sclerosis Journal, 2020, 26, 737-740.	3.0	14
8	Drug Treatment of Clinically Isolated Syndrome. CNS Drugs, 2019, 33, 659-676.	5.9	12
9	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Current Opinion in Neurology, 2019, 32, 365-377.	3.6	73
10	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change. Current Opinion in Neurology, 2019, 32, 327-337.	3.6	32
11	Recommendations for cerebrospinal fluid analysis. Folia Microbiologica, 2019, 64, 443-452.	2.3	8
12	Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Safety, 2019, 42, 633-647.	3.2	18
13	Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis – a pilot study. Acta Ophthalmologica, 2018, 96, e309-e314.	1.1	12
14	Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2017, 136, 360-364.	2.1	14
15	Cerebrospinal fluid and serum levels of interleukin-8 in patients with multiple sclerosis and its correlation with Q-albumin. Multiple Sclerosis and Related Disorders, 2017, 14, 12-15.	2.0	22
16	T- lymphocytes and B-lymphocytes ant their role in multiple sclerosis. Neurologie Pro Praxi, 2017, 18, 318-321.	0.1	0
17	Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. Journal of the Neurological Sciences, 2016, 361, 117-121.	0.6	26
18	Stable isotope dilution ultra-high performance liquid chromatography–tandem mass spectrometry quantitative profiling of tryptophan-related neuroactive substances in human serum and cerebrospinal fluid. Journal of Chromatography A. 2016, 1437, 145-157.	3.7	43

JAN MARES

#	Article	IF	CITATIONS
19	Long-term safety and efficacy of teriflunomide. Neurology, 2016, 86, 920-930.	1.1	108
20	Orthostatic hypotension is associated with decreased cerebrospinal fluid levels of chromogranin A in early stage of Parkinson disease. Clinical Autonomic Research, 2015, 25, 339-342.	2.5	4
21	Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study. Journal of Neural Transmission, 2015, 122, 273-277.	2.8	23
22	Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis. Journal of the Neurological Sciences, 2014, 342, 62-68.	0.6	40
23	Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. Journal of the Neurological Sciences, 2014, 343, 120-124.	0.6	58
24	Intrathecal synthesis in particular types of multiple sclerosis. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2014, 158, 124-126.	0.6	7
25	A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology, 2013, 260, 984-997.	3.6	205
26	Recommendations for the Use of Prolongedâ€Release Fampridine in Patients with Multiple Sclerosis (<scp>MS</scp>). CNS Neuroscience and Therapeutics, 2013, 19, 302-306.	3.9	11
27	Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson's disease. Journal of Neural Transmission, 2012, 119, 353-362.	2.8	25
28	Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome. Neurological Research, 2011, 33, 415-420.	1.3	31
29	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex [®]), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology, 2011, 18, 1122-1131.	3.3	364
30	CSF markers of neurodegeneration in Parkinson's disease. Journal of Neural Transmission, 2010, 117, 1177-1181.	2.8	57
31	New laboratory markers in diagnosis of alzheimer dementia. Neurological Research, 2009, 31, 1056-1059.	1.3	10
32	The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases. Neurological Sciences, 2009, 30, 1-7.	1.9	13
33	CORRELATION OF THE IGG INDEX AND OLIGOCLONAL BANDS IN THE CEREBROSPINAL FLUID OF PATIENTS WITH MULTIPLE SCLEROSIS. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2008, 152, 247-249.	0.6	17
34	Applications of new laboratory marker assays in neurological diagnoses - A pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2005, 149, 265-266.	0.6	3
35	Applications of new laboratory marker assays in neurological diagnoses - a pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2005, 149, 265-6.	0.6	2
36	USE OF CYSTATIN C DETERMINATION IN CLINICAL DIAGNOSTICS. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2003, 147, 177-180.	0.6	17

#	Article	IF	CITATIONS
37	Use of cystatin C determination in clinical diagnostics. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2003, 147, 177-80.	0.6	7
38	Correlation between retinal oxygen saturation and the haemodynamic parameters of the ophthalmic artery in healthy subjects. Acta Ophthalmologica, 0, , .	1.1	1